

Datasheet: HCA306

Description:	HUMAN ANTI RANIBIZUMAB
Specificity:	RANIBIZUMAB
Other names:	Lucentis
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD29858
Isotype:	HuCAL Fab monovalent
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form

A monovalent human recombinant Fab (lambda light chain) selected from the HuCAL® phage display library, expressed in *E. coli*. The antibody is tagged with a DYKDDDDK tag and a HIS-tag (HHHHHH) at the C-terminus of the antibody heavy chain. This antibody is supplied as a liquid.

Preparation

Metal chelate affinity chromatography

Buffer Solution

Phosphate buffered saline

Preservative Stabilisers

0.01% Thiomersal

Approx. Protein Concentrations

Antibody concentration 0.5 mg/ml

Immunogen

Ranibizumab

Specificity

Human Anti-Ranibizumab Antibody, clone AbD29858 is a non-inhibitory, anti-idiotypic antibody in monovalent Fab format that specifically recognizes the monoclonal antibody drug ranibizumab and ranibizumab when in complex with recombinant human vascular endothelial growth factor A (VEGF-A). It does not recognize free human VEGF-A or bevacizumab. This antibody can be used to measure levels of free ranibizumab and biosimilars in patient samples.

Clone AbD29858 can be used to develop a pharmacokinetic (PK) antigen capture format assay to

measure free ranibizumab that has been captured via immobilized VEGF-A.

Ranibizumab (Lucentis) is a humanized Fab fragment antibody (VH3-23/kappa1), originating from the same parental mouse antibody as bevacizumab (Avastin); it has 4 amino acid exchanges in the heavy chain and 1 amino acid exchange in the light chain compared to bevacizumab. Ranibizumab was first approved to treat wet age-related macular degeneration (AMD), a common form of age-related vision loss. It is also approved for the treatment of macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Ranibizumab inhibits angiogenesis by binding to VEGF-A, blocking its interaction with VEGF receptors on the surface of endothelial cells, and thus preventing the subsequent growth of new blood vessels.

[View a summary of all anti-ranibizumab antibodies](#)

Affinity	The monovalent intrinsic affinity of AbD29858 was measured as $K_D=18$ nM by real time, label-free molecular interaction analysis on immobilized VEGF/ranibizumab complex.
ELISA	Clone AbD29858 can be used in a direct or indirect ELISA on ranibizumab or as a detection reagent for free ranibizumab captured via immobilized VEGF-A. Protocol: PK antigen capture ELISA to measure free drug
Storage	Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee	12 months from date of despatch
Acknowledgements	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Lucentis is a trademark of Genentech His-tag is a trademark of EMD Biosciences.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: #: https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf
Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual

Related Products

Recommended Useful Reagents

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

North & South America Tel: +1 800 265 7376
Fax: +1 919 878 3751
Email: antibody_sales_us@bio-rad.com

Worldwide Tel: +44 (0)1865 852 700
Fax: +44 (0)1865 852 739
Email: antibody_sales_uk@bio-rad.com
'M371749:200612'

Europe Tel: +49 (0) 89 8090 95 21
Fax: +49 (0) 89 8090 95 50
Email: antibody_sales_de@bio-rad.com

Printed on 11 Aug 2020

© 2020 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)